PHARMSTAR PHARMACEUTICALS, INC.

Formerly known as

Big Star Media Group, Inc.

INITIAL COMPANY INFORMATION AND DISCLOSURE STATEMENT
AS OF THE QUARTER ENDED DECEMBER 31, 2010, AND THE FISCAL YEAR ENDED SEPTEMBER 30, 2010

EFFECTIVE FEBRUARY 28, 2011, THE COMPANY ACQUIRED A 95.3% INTEREST IN PHARMSTAR PHARMACEUTICALS, INC., A NEVADA CORPORATION.

THE FINANCIAL DATA ACCOMPANYING THIS REPORT REFLECTS THE OPERATIONS OF BIG STAR MEDIA GROUP, INC. THROUGH 12/31/10, THE COMPANY INFORMATION AND DISCLOSURE DISCUSS THE NEW FOCUS OF THE BUSINESS OF THE COMPANY, NOW KNOWN AS PHARMSTAR PHARMACEUTICALS, INC., EFFECTIVE AFTER FEBRUARY 28, 2011.

Table of Contents

Part A General Company Information

Item I The exact name of the issuer and its predecessor (if any).

Pharmstar Pharmaceuticals, Inc. (effective as of March 28, 2011)

Big Star Media Group, Inc. (9/1/09)

Blue Wireless & Data, Inc. (10/04/04)

Reva, Inc. (5/12/03)

World Wide Video, Inc. (4/9/98)

Item II The address of the issuer's principal executive offices.

3791 North Wesleyan Boulevard

Rocky Mount, North Carolina 27804

Phone: (919) 794-7000

www.pharmstarinc.com

Pink Sheets: BMGI (awaiting ticker change from FINRA)

Item III The jurisdiction(s) and date of the issuer's incorporation or organization.

Pharmstar, Inc. ("Pharmstar" or "BMGI" or the "Company") was originally incorporated in the state of Colorado on April 9, 1998 under the name, World Wide Video, Inc. On May 12, 2003 the Company changed its name to Reva, Inc. In October of 2004 the Company changed domicile from Colorado to Delaware, and changed its name to Blue Wireless & Data, Inc. On September 2, 2009 the Company changed its name to Big Star Media Group, Inc. On March 11, 2011 the Company changed its name to Pharmstar Pharmaceuticals, Inc. and is in the process of completing this name change with FINRA.

Part B Share Structure

Item IV The exact title and class of securities outstanding.

In answering this item, provide the exact title and class of each class of outstanding securities. In addition, please provide the CUSIP and trading symbol.

CLASS	CUSIP #	TRADING SYMBOL
Common Stock	Cusip # 08963P 102	BMGI
Preferred Stock, Series A	Cusip # 08963P 102	BMGI
Preferred Stock, Series B	Cusip # 08963P 102	BMGI
Preferred Stock, Series C	Cusip # 08963P 102	BMGI

Item V Par or stated value and description of the security.

A. *Par or Stated Value*. Provide the par or stated value for each class of outstanding securities.

CLASS	PAR VALUE
Common Stock	$.025
Redeemable Preferred Stock, Series A	$.00001
Redeemable Preferred Stock, Series B	$.00001
Redeemable Preferred Stock, Series C	$.00001

B. *Common or Preferred Stock*.

1. For common equity, describe any dividend, voting and preemption rights.

   No dividends are pending, no preemptive rights are pending; common shares are entitled to one vote.

2. For preferred stock, describe the dividend, voting, conversion and liquidation rights as well as redemption or sinking fund provisions.

   Redeemable Preferred Stock, Series A

   Dividend Rate and Rights. Holders of the Series A Preferred Stock shall be entitled to receive dividends or other distributions with the holders of the Corporation's common stock, par value $.0001 (the "Common Stock") on an as converted basis when, as, and if declared by the Directors of the Corporation.

   Voting. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast five million votes for each share of Series A Preferred Stock held. Except as provided by law or by the other provisions of this Certificate, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.

Conversion. Each share of Series A Preferred Stock shall be convertible, at the option of either (i) the holder thereof or (ii) the Corporation, at any time, into the same number of fully paid and nonassessable shares of Common Stock.

Redeemable Preferred Stock, Series B

Dividend Rate and Rights. Holders of the Series B Preferred Stock shall be entitled to receive dividends or other distributions with the holders of the Corporation's common stock, par value $.0001 (the "Common Stock") on an as converted basis when, as, and if declared by the Directors of the Corporation.

Voting. Holders of the Series B Preferred Stock have no voting rights.

Conversion/Redemption. The shares of the Preferred Stock are redeemable over a two (2) year period. The shares are redeemable such that one eighth (1/8) of the shares of Preferred Stock purchased by the Holder per the Subscription Agreement (the "Redemption Shares") are redeemable each quarter over the eight subsequent, consecutive 90 day quarters commencing six (6) months following the original issuance date of the Preferred Stock by the Corporation to the Holder. Each of the Redemption Shares is redeemed at $7.00 per share (a 20% annualized rate of return based on a valuation of $5.00 per share of the Preferred Stock over a two year period). Once the Corporation has received the Redemption Shares from the Holder after a Redemption Date, the Redemption Shares may be redeemed, at the sole discretion of the Corporation, in cash, or in shares of the Corporation's Common Stock payable at a 20% discount to the VWAP on the Redemption Date.

Liquidation. Upon any liquidation, dissolution or winding-up of the Corporation, the holders of the Series B Preferred Stock shall be entitled to receive out of the assets of the Corporation an amount equal to the $5.00 per share, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then in priority behind the holders of the Series A Preferred Stock the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

Redeemable Preferred Stock, Series C

Dividend Rate and Rights. Holders of the Series C Preferred Stock shall be shall be eligible for a 10% dividend, payable at the end of each fiscal quarter. These dividend payments will be made only at the discretion of the Directors of the Corporation, and only when the Corporation is in a positive current earnings position.

Voting. Holders of the Series C Preferred Stock have no voting rights.

Conversion/Redemption. Conversion rights commence the twelfth month after holder's purchase of the Series C Preferred Stock. Such stock may be converted

into shares of common stock on a pro rata basis at a conversion factor of 20% of the total outstanding common stock at the time of conversion.

Liquidation. Upon any liquidation, dissolution or winding-up of the Corporation, the holders of the Series C Preferred Stock shall be entitled to receive out of the assets of the Corporation an amount equal to the $2.00 per share, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then in priority behind the holders of outstanding senior securities the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full.

3. Describe any other material rights of common or preferred stockholders.

None.

4. Describe any provision in issuer's charter or by-laws that would delay, defer or prevent a change in control of the issuer.

None.

Item VI The number of shares or total amount of the securities outstanding for <u>each class</u> of securities authorized.

In answering this item, provide the information below for <u>each class</u> of securities authorized**.** Please provide this information (i) as of the end of the issuer's most recent fiscal quarter and (ii) as of the end of the issuer's last two fiscal years.

(i) Period end date;
(ii) Number of shares authorized;
(iii) Number of shares outstanding;
(iv) Freely tradable shares (public float);
(v) Total number of beneficial shareholders; and
(vi) Total number of shareholders of record.

	PERIOD END DATE	NUMBER OF SHARES AUTHORIZED	NUMBER OF SHARES OUTSTANDING	FREELY TRADABLE SHARES	TOTAL NUMBER OF BENEFICIAL SHAREHOLDERS	TOTAL NUMBER OF SHAREHOLDERS OF RECORD
COMMON STOCK	12/31/2010	100,000,000,000	22,426,782	10,100,343	2	903
PREF. STOCK, SERIES A	12/31/2010	*	100	-	-	1
PREF. STOCK, SERIES B	12/31/2010	*	-	-	-	-
PREF. STOCK, SERIES C	12/31/2010	*	-	-	-	-
COMMON STOCK	9/30/2010	100,000,000,000	4,372,606,626 **	2,300,857,500	1	902
PREF. STOCK, SERIES A	9/30/2010	*	100	-	-	-
PREF. STOCK, SERIES B	9/30/2010	*	-	-	-	-
PREF. STOCK, SERIES C	9/30/2010	*	-	-	-	-
COMMON STOCK	9/30/2009	500,000,000	63,673,626	8,809,310	5	359
PREF. STOCK, SERIES A	9/30/2009	*	-	-	-	-
PREF. STOCK, SERIES B	9/30/2009	*	-	-	-	-

* Total of 10 million preferred stock authorized

** Pre-reverse stock split

Part C Business Information

Item VII The Name and address of the transfer agent

Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
Phone (732) 872-2727
Fax (732) 872-2728
www.oldemonmouth.com

Olde Monmouth Stock Transfer Co., Inc. is registered under the Exchange Act and is an SEC approved transfer agent.

Item VIII The nature of the issuer's business.

Historically (prior to February 28, 2011), the Company was an entertainment and information distribution company focused on web-based presentations of live music events, the promotion of new musical talent, film production, and corporate messaging. Effective February 28, 2011 the Company acquired a majority interest in Pharmstar Pharmaceuticals, Inc., a Nevada corporation, and on March 11, 2011 amended its articles of incorporation to reflect a name change to Pharmstar Pharmaceuticals, Inc.

(EFFECTIVE SUBSEQUENT TO 2/28/11)
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever.

In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.

1. The form of organization of the issuer

Pharmstar is a Delaware Corporation.

2. The year that the issuer (or any predecessor) was organized

Pharmstar Pharmaceuticals, Inc. (Delaware) was organized on March 11, 2011.

Previous predecessors:

Predecessor	Organized

Big Star Media Group, Inc.	9/1/09
Blue Wireless & Data, Inc.	10/04/04
Reva, Inc.	5/12/03
World Wide Video, Inc.	7/16/97

3. The issuer's fiscal year end date

The Issuers Fiscal year-end date is September 30.

4. Whether the issuer (or any predecessor) has been in bankruptcy, receivership or any similar proceeding

Issuer has not been in any bankruptcy, receivership, or any similar proceedings.

5. Any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets

On May 12, 2003 World Wide Media, inc. merged with Reva, Inc., a Delaware corporation, resulting in a change of name and domicile from Colorado to Delaware.

On July 12, 2005, the Company amended it Articles of Incorporation to increase the number of authorized common shares from 200,000,000 (Two Hundred Million) shares to 500,000,000 (Five Hundred Million) shares.

On September 22, 2010 the Company amended it Articles of Incorporation to increase the number of authorized common shares from 500,000,000 (Five Hundred Million) shares to 100,000,000,000 (One Hundred Billion) shares.

Effective February 28, 2011, the Company acquired a 95.3% interest in Pharmstar Pharmaceuticals, Inc., a Nevada corporation. This transaction will be accounted for as a reverse acquisition for accounting purposes as a result of a change in control.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments

None.

7. Any change of control

Effective February 28, 2011, Pharmstar Incorporated became owner of 80% of the outstanding common stock of the Company. Effective March 31, 2011, Howard Phykitt became owner of 100% of the outstanding Series A preferred stock of the Company

8. Any increase of 10% or more of the same class of outstanding equity securities

CLASS	DATE	ISSUED TO	% INCREASE
Common	11/30/2010	Jack Haigh	21.7%
Preferred A	12/15/2009	PATB, LLC *	104%

* PATB's ownership of the Preferred A shares were conveyed to Howard Phykitt on 3/31/11

9. Any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization

On May 9, 2006 the Company effected a reverse stock split of its common shares on a 1 for 50 basis.

On October 18, 2010 the Company effected a reverse stock split of its common shares on a 1 for 2500 basis.

10. Any delisting of the issuer's securities by any securities exchange or deletion from the OTC Bulletin Board

In March 2006 the Company was delisted from the OTC Bulletin Board Exchange for failure to make timely filings.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations and any current, past or pending trading suspensions by a securities regulator. State the names of the principal parties, the nature and current status of the matters, and the amounts involved.

None.

A. <u>Business of Issuer</u>.

Pharmstar Pharmaceuticals, Inc. has been researching for over 15 years to convert common aspirin into a much more effective and safer form. Located in Rocky Mount, NC, the founder and his group have been validating, testing and stabilizing its signature product, AQUAPRIN.

The current research and production facility is not large enough, nor does it meet FDA regulation to properly produce pharmaceuticals. Therefore, the company is raising the necessary capital to purchase a new, existing building to serve as the commercial production facility for AQUAPRIN, and all extension line products. This new facility is also located in Rocky Mount, NC.

The Company's newly acquired pharmaceutical business is not a "start-up" operation. The Company's new management, since 1992, have performed, and continue performing all the costly research, development and packaging engineering, product stability, shelf-life testing and quality-control for AQUAPRIN. The product and several line extensions are now ready for scale-up and commercialization. AQUAPRIN will be manufactured in accordance with the current FDA Analgesics Monograph, appearing in the "permitted combinations" section of the Federal Register and in the USP under the "Effervescent Aspirin" monograph.

PharmStar expects to be a leader in the pain management field, and to capture a substantial segment of the analgesic, cardio protective, anti-thrombotic and antipyretic pharmacotherapeutic market, owing to AQUAPRIN and other line extension products significant competitive advantages. AQUAPRIN Is an instantly dissolving, fast-acting, non-acidic, safer, more potent drinkable derivative of aspirin, which virtually eliminates irritation to the GI-tract, and is a more effective and efficient method of delivering salicylates into the blood stream, achieving almost peak blood plasma levels in 7 to 10 minutes. Moreover, it

contains therapeutically active levels of potassium, which acts also as an antacid in neutralizing stomach acid. Potassium also lowers blood pressure and helps to dilate blood vessels allowing for better blood circulation.

1. The issuer's primary and secondary SIC Codes

The Issuer's SIC Codes are 2834-04, 2834-98, 5122-03, and 8731-08.

2. If the issuer has never conducted operations, is in the development stage, or is currently conducting operations

The Issuer is currently in the development stage.

3. Whether the issuer is or has at any time been a "shell company"[1];

The Issuer is not considered a Shell Company pursuant to Securities Act Rule 405.

4. The names of any parent, subsidiary, or affiliate of the issuer, and its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure statement

As of March 22, 2011, the following entity is a subsidiary of the Company:

SUBSIDIARY	BUSINESS PURPOSE	METHOD OF OPERATION	OWNERSHIP	INCLUDED IN FINANCIALS
Pharmstar Pharmaceuticals, Inc. (a Nevada corporation)	Holds assets and operations related to the manufacture of Aquaprin™	Corporation	95.3%	No

The Issuer has the following affiliates, by virtue of their status as officers or directors of the Company:

AFFILIATE	BUSINESS PURPOSE	METHOD OF OPERATION	OWNERSHIP	INCLUDED IN FINANCIALS
Pharmstar Incorporated	Holding company	Corporation	80%	No

5. The effect of existing or probable governmental regulations on the business

No effect expected.

6. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers

Over the last two fiscal years the Company has spent an insignificant amount of money on research and development activities.

7. Costs and effects of compliance with environmental laws (federal, state and local)

None.

8. The number of total employees and number of full-time employees.

The Company currently has four full-time employees.

Item IX The nature of products or services offered.

A. Principal products or services, and their markets

The principal product offered by Pharmstar will be Aquaprin™, an FDA-approved Over-the-Counter (OTC) liquid pain reliever. The market is the retail over-the-counter pharmaceuticals sector.

B. Distribution methods of the products or services

Pharmstar plans to distribute its product through typical pharmaceutical retail outlets, by utilizing existing wholesale pharmaceutical distribution networks.

C. Status of any publicly announced new product or service

AQUAPRIN™ has been approved by the FDA, all Patents Pending. The product and several line extensions are now ready for scale-up and commercialization.

AQUAPRIN will be manufactured in accordance with the current FDA Analgesics Monograph, appearing in the "permitted combinations" section of the Federal Register and in the USP under the "Effervescent Aspirin" monograph.

D. Competitive business conditions, the issuer's competitive position in the industry, and methods of competition

AQUAPRIN has no known competition with respect to its pharmacological merits. And the proprietary technology, trade secrets and "know-how" involved in its manufacture are unknown to anyone in the industry.

AQUAPRIN is only up against the brand names which have over several decades entrenched themselves in the minds of consumers. However, after a period of aggressive marketing, education and consumer recognition, AQUAPRIN should quickly ascend to the top ranks of the analgesic pantheon.

In Europe, where soluble aspirins dominate, most are fine suspensions, and not completely dissolved solutions. The majorities are sodium-based, take a few minutes to dissolve and taste bad, or they are calcium-based, preventing total dissolution of the aspirin. There is also a French soluble analgesic product, Aspégic; however, it contains the exotic dl-form of lysine, and could never win FDA approval in the U.S. None of these foreign products can in any event be marketed in the USA since they do not fall within any FDA-approved monograph. The only soluble form of aspirin sold in this country is Alka-Seltzer, which has excessive sodium (1.2 grams per 650 mg. dose), and cannot be used for chronic pain daily doses or by older people who are on sodium-

restricted diets. It also generates distending amounts of gas. AQUAPRIN is, on the other hand, a 100% potassium-based, low-effervescence product.

E. Sources and availability of raw materials and the names of principal suppliers

Church & Dwight is the primary supplier of potassium, the Company has a proprietary, confidential relationship with its primary supplier of aspirin.

F. Dependence on one or a few major customers

The Company does not depend on one of a few major customers.

G. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration

AQUAPRIN™ has several patents pending.

H. The need for any government approval of principal products or services and the status of any requested government approvals.

The FDA has approved AQUAPRIN™ for commercialization scale production.

Item X The nature and extent of the issuer's facilities.

Pharmstar owns a research laboratory and small-scale production facility in Rocky Mount, NC. The company plans to begin a scaled up production facility for retail distribution in the near future.

Part D Management Structure and Financial Information

Item XI The name of the chief executive officer, members of the board of directors, as well as control persons.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Officers and Directors. In responding to this item, please provide the following information for each of the issuer's executive officers, directors, general partners and control persons, as of the date of this information statement:

1. Full name;
2. Business address;
3. Employment history (which must list all previous employers for the past 5 years, positions held, responsibilities and employment dates);
4. Board memberships and other affiliations;
5. Compensation by the issuer; and
6. Number and class of the issuer's securities beneficially owned by each such person.

1. Howard Phykitt, Director, Chief Executive Officer
2. 3791 North Wesleyan Boulevard, Rocky Mount, North Carolina 27804
3. Mr. Phykitt has extensive experience in the design and implementation of pharmaceutical manufacturing products. Working with companies such as Monsanto, Warner-Lambert, Durkee Foods, Johnson & Johnson (McNeil), American Home Products and many other pharmaceutical companies, Mr. Phykitt has been tabbed with the bringing a litany of current name brand products to full production. He began his career with Teledyne Isotopes, developing systems for the detection of radioactivity in the late 50's. He moved into the pharmaceutical manufacturing industry in 1975, developing granulation and coating technology that is used today by companies such as Eli Lily and Glaxo Smithkline in the production of pharmaceutical products. In 1984, Mr. Phykitt founded Granutec, Inc. where he developed fluid bed micro-encapsulation for use in the pharmaceutical and agriculture industries. By 1988, Granutec grew to $6 million in sales, and from there to over $40 million in sales by 1990. In 1993, the company had grown to over $60 million in sales to companies such as Walmart, Eckerd, Perry Drug, and Rite Aid. By 1993, Mr. Phykitt began the research and development of a safer, more effective delivery of aspirin products. By 1997, he had received 3 patents in this developing, and through various vehicles and personal investment, began perfecting the development of Aquaprin. After over 17 years of researching, testing, patenting and developing Aquaprin, he is now ready to bring his most important work to the $30 billion pain management industry. Mr. Phykitt is a member of the American Management Association with fluency in FDA regulatory affairs, quality control and manufacturing. Mr. Phykitt attended Columbia University.
4. None
5. Undetermined at this time.

6. 805 million shares, common, through control of Pharmstar Incorporated.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

   None.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

   None.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

   None.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

   None.

C. Disclosure of Family Relationships. Describe any family relationships[2] among and between the issuer's directors, officers, persons nominated or chosen by the issuer to become directors or officers, or beneficial owners of more than five percent (5%) of the any class of the issuer's equity securities.

None.

D. Disclosure of Related Party Transactions. Describe any transaction during the issuer's last two full fiscal years and the current fiscal year or any currently proposed transaction, involving the issuer, in which (i) the amount involved exceeds the lesser of $120,000 or one percent of the average of the issuer's total assets at year-end for its last

[2] The term "family relationship" means any relationship by blood, marriage or adoption, not more remote than first cousin.

three fiscal years and (ii) any related person had or will have a direct or indirect material interest. Disclose the following information regarding the transaction:

None.

E. Disclosure of Conflicts of Interest. Describe any conflicts of interest. Describe the circumstances, parties involved and mitigating factors for any executive officer or director with competing professional or personal interests.

None.

Item XII Financial information for the issuer's most recent fiscal period.

The issuer shall provide the following financial statements for the most recent fiscal period (whether fiscal quarter or fiscal year).

1) balance sheet;
2) statement of income;
3) statement of cash flows;
4) statement of changes in stockholders' equity;
5) financial notes; and
6) audit letter, if audited

Such financial statements are hereby incorporated by reference and can be found for the Company's fiscal quarter ended December 31, 2010, and the fiscal year ended September 30, 2011 published as a "*Quarterly Report*", subtitled *"Quarterly report incorporated for the period ended 12/31/10 with annual results for the period ended 9/30/2010."*

Item XIII Similar financial information for such part of the two preceding fiscal years as the issuer or its predecessor has been in existence.

Please provide the financial statements described in Item XII above for the issuer's two preceding fiscal years.

Such financial statements are hereby incorporated by reference and can be found for the Company's fiscal year ended September 30, 2009 published as an "*Annual Report*", subtitled *"Annual Report incorporated for the period ended 9/30/09."*

Item XIV Beneficial Owners.

Name	Address	Security	Shareholdings	Controlled By	Registered Agent
Howard Phykitt	3791 North Wesleyan Boulevard, Rocky Mount, NC 27804	Common	80%	N/A	N/A
Howard Phykitt	3791 North Wesleyan Boulevard, Rocky Mount, NC 27804	Preferred A	100%	N/A	N/A

Item XV **The name, address, telephone number, and email address of each of the following outside providers that advise the issuer on matters relating to operations, business development and disclosure:**

1. Investment Banker

   None.

2. Promoters

   None.

3. Counsel

   Joseph Pittera, Law Offices of Joseph Pittera, 2214 Torrance Boulevard Suite 101, Torrance, California 90501, (310) 328-3588, evlam2000@aol.com.

4. Accountant or Auditor - the information shall clearly (i) describe if an outside accountant provides audit or review services, (ii) state the work done by the outside accountant and (iii) describe the responsibilities of the accountant and the responsibilities of management (i.e. who audits, prepares or reviews the issuer's financial statements, etc.). The information shall include the accountant's phone number and email address and a description of the accountant's licensing and qualifications to perform such duties on behalf of the issuer.

   Monte Waldman (786) 369-5218, Monte Waldman, montewaldcpa@gmail.com. Mr. Waldman is a licensed (Maryland) and active CPA with over 15 years experience in a variety of financial positions as a CPA for both public and private entities.
   (i) Did not provide audit or review services
   (ii) Assisted with the preparation of the financial statements
   (iii) The accountant assisted with the preparation of the financial statements with review by management

5. Public Relations Consultant(s)

   None.

6. Investor Relations Consultant

   Tommy Johnson, 3791 North Wesleyan Boulevard, Rocky Mount, North Carolina 27804, 919-794-7000, investors@pharmstarinc.com.

7. Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement - the information shall include the telephone number and email address of each advisor.

   None.

Item XVI Management's Discussion and Analysis or Plan of Operation.

A. Plan of Operation

Market conditions favoring the new field of Pain Management are now assuming an expansive dimension of therapeutic and commercial opportunity, and PharmStar's AQUAPRIN is primed to assume a position of market leadership. It is especially noted that other major analgesic products are introducing liquid versions of their pain relievers. Liquid versions are beginning to take hold, which is especially good for AQUAPRIN, since it is in liquid form, although much more effective and competitive. Indeed, AQUAPRIN, uniquely fast acting and safer to the stomach, exhibits many important pharmacological, and commercial advantages over all other aspirin products including, especially, aspirin itself. Rapid market penetration is expected owing to AQUAPRIN 's unique selling proposition. AQUAPRIN is also superior in effectiveness than any other OTC pain reliever. In the US, no oral competing products exist, in terms of potency, rapid onset of action, and gastric tolerance. Neither does any competing product exists that can deliver a comparably high percentage of un-degraded salicylates per analgesic or cardio protective dose.

1. It will, for this reason, be strategically launched in such target sectors as AARP, hospitals and nursing home pharmacies, and by direct marketing, with detail samples and technical data, to medical professionals, as well as via special "2-for-1" buying incentives for distributors. Internet banners, infomercials, and consumer hot-lines will likewise be deployed after the initial 6 months, as will dedicated e-commerce, permitting direct purchase of AQUAPRIN from the Company. A special information and product campaign will be aimed toward emergency medical service organizations.

2. The Company recognizes the difficulty for a new product to secure prominent shelf space in drugstores. Its strategy will, therefore, depend on vigorous sales promotion and highly visible point-of-purchase displays at high-traffic consumer corridors. The company feels that the product is so superior to all other OTC pain relievers, that once tried with free samples, the public will demand the product. Also, local-media coupons and direct marketing will be creatively deployed by the Company to get its products distributed. The Company will also attempt to make a strategic alliance with a major pharmaceutical manufacturer and/or a pharmaceutical distribution company.

3. The Company's strategic marketing plan includes English/Spanish promotional, packaging and medicinal insert formats. Overall Hispanic growth demographics show manifold increases in every quadrant of this population sector over the past 3 decades. AQUAPRIN's bilingual debut also translates into easier brand-recognition and penetration of Mexican, Central and South American markets as soon as practicable, and without having to revamp or redesign product packaging or advertising.

4. Once The Company's brand name is established in the market, the public is expected to express its awareness of AQUAPRIN' s benefits by seeking out and purchasing the product on its own initiative. Since there exists no alternative sodium-free soluble analgesic product, AQUAPRIN should enjoy a market dominance.

5. A prescription dose form will be marketed through doctors.

Corporate Funding and Direction

Phase One
Raise $2,800.000 million dollars, which will accomplish the following:

Use of Proceeds (Phase One)
1. Complete construction of R&D laboratory and Pilot production facilities.
2. Provide laboratory and pilot production equipment.
3. Scale up to pilot production capacity.
4. Register Facility and products with the FDA
5. Validate processes & equipment.
6. Do 90 day stabilities to get 2 year dating.
7. Write "Standard Operating Procedures".
8. Expand laboratory area to be able to develop follow on products and line extensions.
9. Establish the manufacture, marketing, and sale of AQUAPRIN in limited quantities with phase 1 funding. Thoroughly engage its professional marketing team to get AQUAPRIN into distribution channels and in to drugstore shelves, hospitals, nursing homes, and into the prescription drug markets and or make licensing and distribution agreements as soon as possible.
10. Continue to develop advanced formulations, improvements and line extensions
11. Complete development of the Insta-Prin Emergency administration technology.
12. Develop several line extension of AQUAPRIN , such as: AQUAPRIN Cough & Cold, AQUAPRIN Cold & Flu, AQUAPRIN Menstrual Pain. AQUAPRIN Migraine Pain.
13. Conduct clinical claim trials to make specific claims for the product.

Phase Two
Raise $3,600.000 million dollars, which will accomplish the following:

Use of Proceeds (Phase Two)
· Initiate full scale clinical studies in order to meet FDA and FTC requirements to make claims of "fastest acting, Safest, and most effective" analgesic on the market.
- Make leasehold improvements to a physical plant.
- Establish full-scale production capability with phase 2 funding.
- Continue to develop advanced formulations, improvements and line extensions.
- Thoroughly engage its professional marketing team to get AQUAPRIN into retail distribution channels and in to drugstore shelves, hospitals, nursing homes, and into the prescription markets and or make licensing and distribution agreements as soon as possible.
- Complete development of the Insta-Prin emergency administration technology.
- Develop several line extension of AQUAPRIN, such as: AQUAPRIN Cough & Cold, AQUAPRIN Cold & Flu, AQUAPRIN Menstrual Pain, AQUAPRIN Migraine Pain.
- License distribution for European and Asian markets.

B. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Not applicable.

C. Off-Balance Sheet Arrangements.

None.

Part E Issuance History

Item XVII List of securities offerings and shares issued for services in the past two years.

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer (1) within the two-year period ending on the last day of the issuer's most recent fiscal year and (2) since the last day of the issuer's most recent fiscal year.

None.

Part F Exhibits

The following exhibits must be either described in or attached to the disclosure statement:

Item XVIII Material Contracts.

None.

Item XIX Articles of Incorporation and Bylaws.

The Issuer's articles of incorporation and bylaws are hereby incorporated by reference; such documents may be found under the financial reports located under the filings tab for the company (EVFL). The Company's articles of incorporation and bylaws are published as "*Articles of Incorporation – Certificate of Incorporation and Bylaws.*"

Item XX Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

A. In the following tabular format, provide the information specified in paragraph (B) of this Item XX with respect to any purchase made by or on behalf of the issuer or any "Affiliated Purchaser" (as defined in paragraph (C) of this Item XX) of shares or other units of any class of the issuer's equity securities.

ISSUER PURCHASES OF EQUITY SECURITIES				
Period	Column (a) Total Number of Shares (or Units) Purchased	Column (b) Average Price Paid per Share (or Unit)	Column (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Column (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
-	-	-	-	-

There have been no issuer repurchases of securities.

Item XXI Issuer's Certifications.

I, Howard Phykitt, certify that:

1. I have reviewed this Initial Company Information and Disclosure Statement of Pharmstar Pharmaceuticals, Inc, formerly known as Big Star Media Group, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operation and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: March 25, 2011

/s/ Howard Phykitt
Chief Executive Officer